As a clinical-stage biopharmaceutical company, Kalypsys’ engages in the continued advancement of compounds to clinical proof-of-concept.
We have a number of clinical stage compounds available for license:
KD7040
Topically administered iNOS inhibitor exiting a Phase IIa trial in post-herpetic neuralgia.
KD7332
Orally administered iNOS inhibitor poised for IND filing that has shown efficacy in a wide range of pain and inflammation models.
KD3010
Orally administered PPAR δ -selective agonist which has shown preclinical potential in models of diabetes and dyslipidemia, and is poised to enter Phase II. PPAR δ -selective agonists are currently being evaluated in preclinical models of nonalcoholic steatohepatitis (NASH) and diabetic wound healing. Phase I Clinical Trial Data Poster | The Effect of KD3010 on Glucose Homeostasis Poster
We sincerely value the opportunity to work collaboratively on our clinical stage compounds. Please visit our Partnering page for additional information or contact Jackie Gulick at jgulick@kalypsys.com to discuss opportunities in this space.
